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Abstract
Background: To compare the activity and toxicity of docetaxel/carboplatin (DC) doublet vs single agent docetaxel
(D) as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC).
Methods: Patients pre-treated with front-line platinum-free regimens, were randomized to receive either
docetaxel/carboplatin (DC), (docetaxel 50 mg/m
2; carboplatin AUC4; both drugs administered on days 1 and 15) or
docetaxel single-agent (D), (docetaxel 50 mg/m
2 on days 1 and 15).
Results: Response rate was similar between the two arms (DC vs D: 10.4% vs 7.7%; p = 0.764). After a median
follow-up time of 28.0 months for DC arm and 34.5 months for D arm, progression free survival (PFS) was
significantly higher in the DC arm (DC vs D:3.33 months vs 2.60 months; p-value = 0.012), while no significant
difference was observed in terms of overall survival (OS) (DC vs D: 10.3 months vs 7.70 months; p-value = 0.550).
Chemotherapy was well-tolerated and grade III/IV toxicities were relatively infrequent. No toxic deaths were
observed.
Conclusions: This study has not achieved its primary objective of significant OS prolongation with docetaxel/
carboplatin combination over single-agent docetaxel in patients who had not received front-line docetaxel;
however, the docetaxel/carboplatin combination was associated with a significant clinical benefit in terms of PFS.
Background
Lung cancer represents a major health problem world-
wide. It is the leading cause of cancer-related death in
Europe [1], with a 5-year survival of approximately 15%
for all stages [2]. Non-Small Cell Lung Cancer (NSCLC)
represents approximately 80-85% of all lung carcinomas.
The vast majority of patients are diagnosed with
advanced, unresectable disease (stage IIIB/IV) which
remains incurable with a 5-year survival rate of less than
5% [3].
Front-line chemotherapy for the treatment of patients
with inoperable locally advanced or/and metastatic
NSCLC has been substantially improved during the last
decade with the introduction of new cytotoxic agents
such as gemcitabine, vinorelbine, gemcitabine, paclitaxel,
docetaxel and pemetrexed; combination of these agents
with a platinum compound represents the standard of
care for front-line treatment [4]. Nevertheless, several
individual phase III trials have demonstrated that there
is no difference between platinum-based and platinum-
free doublets in terms of overall response rate (ORR),
time to tumor progression (TTP) and overall survival
(OS), while platinum-free doublets have a more favor-
able toxicity profile [5-9]. However, NSCLC patients will
inevitably experience tumor progression and at that
time some patients will still have a good Performance
Status (PS) and will be suitable for second-line
treatment.
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tration of docetaxel in the second-line setting was super-
ior in terms of OS compared to best supportive care [10]
and improved TTP and 1-year survival rate compared to
vinorelbine or ifosfamide [11]. Furthermore, the adminis-
tration of pemetrexed in the second-line setting was asso-
ciated with an OS comparable to that of docetaxel with a
more favorable toxicity profile [12].
The epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) erlotinib and gefitinib are also
considered as an alternative for second-line treatment
since erlotinib was associated with a superior OS com-
pared to placebo [13] whereas gefitinib was associated
with a comparable OS when compared to docetaxel
[14]. However, results of second-line treatment for
patients with relapsing or progressing disease are gener-
ally poor, with response rate of less than 10% and OS of
7-8 months [10-14]. One logical approach to improve
these results is to evaluate combination regimens. Two
phase II trials have evaluated the docetaxel/carboplatin
combination as second-line treatment in NSCLC
demonstrating encouraging results with an ORR of
≥20% and a median OS of 8 months [15,16]. However,
this combination has not been compared against the
standard second line treatment with single agent doce-
taxel. Furthermore, given that there is no clear evidence
that platinum-based doublets offer a survival benefit
against third-generation platinum-free regimens [17]
there will be a number of NSCLC patients treated with
platinum-free combinationsa sf i r s tl i n et r e a t m e n ta n d
for whom a platinum-based doublet as second line treat-
ment will be a logical approach. These observations pro-
vided the rationale for this phase III trial which was
conducted in order to determine whether the combina-
tion of docetaxel/carboplatin provides any therapeutic
benefit compared to single-agent docetaxel.
Methods
Patients
Eligible patients were aged 18 years or older, with histo-
logically or cytologically confirmed, unresectable locally
advanced (stage IIIB with pleural or pericardial effusion)
or metastatic (stage IV) NSCLC, that progressed or
recurred after one previous platinum-free and doce-
taxel-free chemotherapy regimen. Patients had to have a
life expectancy of more than 3 months and a World
Health Organization (WHO) performance status (PS) of
≤ 2, and adequate organ function [serum bilirubin ≤ 1.5
times the upper normal limit (UNL); AST and ALT ≤
2.5 UNL in the absence of perceptible liver metastases,
or ≤ 5 UNL in the presence of liver metastases; serum
creatinine ≤ 1.5 times the UNL; neutrophils ≥ 1.5 × 10-
9/L, and platelets ≥ 100 × 10-9/L]. Patients with known,
symptomatic central nervous system metastases were
ineligible. Other eligibility criteria were: absence of
active infection, history of significant cardiac disease
(unstable angina, congestive heart failure, myocardial
infarction within the previous 6 months, ventricular
arrhythmias) or malnutrition (loss of ≥ 20% of the origi-
nal body weight). All patients gave written informed
consent to participate in the study and the trial was
approved by the Ethics and Scientific Committees of the
participating centers. The study was conducted accord-
ing to the Helsinki Declaration and Good Clinical Prac-
tice guidelines.
Treatment
For the docetaxel/carboplatin arm (DC), treatment con-
sisted of docetaxel at a dose of 50 mg/m
2, administered
a sa6 0 - m i ni vi n f u s i o no nd a y s1a n d1 5 ;c a r b o p l a t i n
was administered on days 1 and 15 as a 90-min intrave-
nous infusion, at a dose of AUC 4. Standard pre- and
post-medication with 8 mg oral dexamethasone, at 7 h
and 1 h before the docetaxel infusion, and 8 mg twice
daily for a further 3 days, was used to reduce the risk of
allergic reactions and fluid-retention syndrome that can
be associated with docetaxel administration. For the
docetaxel single-agent arm (D), treatment consisted of
docetaxel at a dose of 50 mg/m
2 on days 1 and 15 after
appropriate corticosteroid pre- and post-medication.
The every two weeks schedule was selected because of
its more favorable toxicity profile [18-20]. Treatment
was repeated every four weeks, for both arms. Treat-
ment was continued until disease progression, the
appearance of unacceptable toxicity, or patient’sw i t h -
drawal of consent, for a maximum of 6 cycles.
Βaseline and follow-up assessments
Baseline assessment included a complete medical his-
tory, evaluation of performance status, physical exami-
nation and vital signs, 12-lead ECG, blood tests
(complete blood cell count with differential and blood
chemistry), chest X-rays and computed tomography
scans of the chest, abdomen and brain and a whole-
body radionuclide bone scan. Baseline evaluation had to
be performed within two weeks prior to therapy initia-
tion. All measurable lesions were identified at baseline
and were monitored throughout. A complete medical
history and a detailed physical examination with com-
plete blood cell count with differential and blood chem-
istry, ECG and a chest X-ray were performed before
each treatment administration to assess the disease sta-
tus and treatment toxicity. After completion of study
treatment, patients were followed every month until the
development of disease progression. Third-line therapy
included best supportive care, palliative radiotherapy, or
chemotherapy according to the discretion of the respon-
sible physician.
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Response assessment was evaluated every two che-
motherapy cycles, and every one month after treatment
completion. Objective tumor responses were evaluated
according to RECIST criteria [21]. All CT scans were
reviewed by an independent radiologist. Toxicity was
evaluated before each chemotherapy administration and
was reported according to National Cancer Institute
Common Toxicity Criteria, version 2 [22].
Statistical analysis
Patients were centrally randomized by computer soft-
ware to a 1:1 ratio, to receive either DC or D. The ran-
domization to each arm was done by stratification
according to PS, stage of disease and response to front-
line treatment.
The primary end-point was overall survival (OS); sec-
ondary endpoints included overall response rate (ORR),
safety profile and progression-free survival (PFS) asso-
ciated with each regimen. The study was designed to
have 90% power (a = 0.05, two-sided log-rank test) to
detect an increase in median survival from 4 months for
the single agent docetaxel arm [18] to 8 months for the
docetaxel/carboplatin arm [15,16] at the statistically sig-
nificant level of 5%. Sixty-five patients should be
enrolled in each arm to achieve the statistical
requirements.
Analysis was performed on an intent-to-treat basis.
Duration of tumor response is measured from the date
the first objective response (complete or partial) was
observed to the first date of tumor progression or death
from any cause. The PFS was measured from study
entry until the day of the first evidence of disease pro-
gression whereas OS from the date of study entry to
death or last contact. The probability of survival was
calculated by the method of Kaplan-Meier [23] and
tested for differences by using the log-rank test. All tests
were two-sided and were considered significant when
the resulting p-value was ≤ 0.05. This study is registered
with ClinicalTrials.gov, number NCT00430651.
Results
Patient demographics
From 08/2004 until 03/2008, 67 patients were enrolled
i nt h eD Ca r ma n d6 5i nt h eDa r m .T w e l v e( 1 7 . 9 % )
patients completed treatment as per protocol in the DC
arm and 9 (13.8%) patients in the D arm (p-value =
0.636). Early treatment discontinuation before the
administration of 6 chemotherapy cycles, because of dis-
ease progression, occurred in 49 (73.1%) and 51 (78.5%)
patients in the DC and the D arm, respectively. Four
(6.0%) and two (3.1%) patients in the DC and D arms,
respectively discontinued treatment due to adverse
events (p-value = 0.680). These patients were considered
to have progressive disease in the intention-to-treat ana-
lysis. Patients’ characteristics are presented in Table 1.
Compliance with the treatment
A total of 228 and 196 chemotherapy cycles were admi-
nistered in the DC and D arms respectively; the median
number of cycles received per patient was 3.0 (range 1-
6) in the DC arm and 2.0 (range 1-6) in the D arm. The
median duration of cycle was 31 days for the DC arm
(range, 27-56 days) and 29 days for the D arm (range
27-47 days). Treatment administration was delayed in
61 (26.8%) DC and in 23 (11.7%) D cycles (p < 0.001).
Twenty eight (45.9%) DC and 5 (21.7%) D cycles were
delayed due to toxicity (both haematological and non-
hematological) (p-value = 0.010). All other cycles were
delayed for reasons not related to treatment or toxicity
(i.e. patient’s request for personal reasons, pending
Table 1 Patients Characteristics
DC
(n = 67)
D
(n = 65)
N (%) N (%) P-value
Age 62 63
Median (min-max) 39 - 78 39 - 83
Sex
Male 64 (95.5) 56 (86.2) P = 0.074
Female 3 (4.5) 9 (13.8)
Performance status
0 26 (38.8) 14 (21.5) P = 0.088
1 33 (49.3) 39 (60.0)
2 8 (11.9) 12 (18.5)
Histological Type
Squamous 16 (23.9) 18 (27.7) Adeno Ca vs Non-Adeno
Ca
P = 0.380
Adeno Ca 26 (38.8) 31 (47.7)
Large Cell 2 (3.0) 1 (1.5)
Mixed 1 (1.5) 1 (1.5)
Other 22 (32.8) 14 (21.5)
No. of Organs
Involved
Median (min- max) 2.00 (1 -
8)
2.00 (1 -
5)
1-2 vs > = 3
P = 0.444
Mann-Whitney
U = 2142.500
P = 0.867
Prior therapy
Paclitaxel 8 (11.9) 7 (10.8) P = 0.109
Response to prior
therapy
CR+PR vs SD+PD
P = 0.799
CR 1 (1.5) 1 (1.5)
PR 7 (10.4) 8 (12.3)
SD 18 (26.9) 19 (29.2)
PD 41 (61.2) 37 (56.9)
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tions were required in 41 (18.0%) DC and in 29 (14.8%)
D cycles (p-value = 0.432). Dose reductions in both
groups were mainly due to haematological toxicity. The
median dose intensity for each drug were 22.1 mg/m
2/
week (range: 11.5-25.0 mg/m
2/week) for docetaxel
(88.2% of planned dose) and 87.1 mg/m
2/week (range:
42.4-153.3 mg/m
2/week) for carboplatin for the DC
arm; in the docetaxel single-agent arm, median dose
intensity for docetaxel was 23.3 mg/m
2/week (range:
12.3-25.0 mg/m
2/week; 93.3% of planned dose). There
was no difference in the percentage of patients who
received third-line treatment between the two arms (DC
vs D: 59.7% vs 47.7%; p = 0.222) (Table 2).
Response to treatment
Overall response rate was similar between the two arms
(DC vs D: 10.4% vs 7.7%; p = 0.764). No complete
responses were observed in both arms, while seven
(10.4%) and five (7.7%) patients achieved a partial
response (PR), in the DC and D arms respectively
(Table 3). More patients in the single-agent arm had
progressive disease (PD) when compared to combination
arm; PD was observed in 46 (68.7%) and 51 (78.5%)
patients, respectively (p = 0.239). The median duration
of response was 4.0 months for the DC arm and 3.33
months for the D arm (p = 0.952).
After a median follow-up time of 28.0 months (min-
max: 20.3-35.7) for DC arm and 34.5 months (min-
max:22.1-46.9) for D arm (p-value = 0.425), the median
PFS was 3.33 months (range: 0.2-23.0 months; 95% CI:
2.59-4.07) and 2.60 months (range: 0.5-17.8 months;
95% CI: 1.74-3.46) (p-value = 0.012; Figure 1) for the
two arms, respectively (Table 3). Ιn addition, the median
OS was 10.27 months for the DC arm (95% CI: 7.07-
13.47) and 7.70 months for D arm (95% CI: 3.39-12.01)
(Log-Rank test, p-value = 0.550) (Figure 2). The esti-
mated 1-year survival rate was 43.8% and 40.3% for the
DC and D arms, respectively. There was no difference
in terms of ORR, PFS or OS between patients who
received paclitaxel in first line treatment and those who
did not, in both groups.
Forty (59.7%) patients in the DC arm and 31 (47.7%)
in the D arm received third-line treatment (p = 0.222).
The majority of patients in both arms received single-
agent chemotherapy. However, there was an imbalance
in the number of patients who received an EGFR
tyrosine kinase inhibitor as third-line treatment (Table 2).
Toxicity
Toxicity was assessed in all chemotherapy cycles and in
all patients. Chemotherapy was in general well-tolerated
and grade III/IV toxicities were relatively infrequent. No
toxic deaths were observed. Table 4 summarizes all
treatment-related toxicities. No significant differences
were observed between the two arms in terms of hema-
tological toxicity, with the exception of thrombocytope-
nia which was more pronounced in the DC arm;
however, in the majority of cases it was of grade I and
II and only two patients in the DC arm experienced
grade III thrombocytopenia. All events resolved without
a n ys e q u e l .T h em o s tf r e q u e n tg r a d eI I I / I Vh e m a t o l o g i -
cal toxicity was neutropenia which occurred in 11
(16.4%) patients in the DC arm and four (7.5%) patients
in the D arm (p = 0.098). In terms of non-hematological
toxicity, mucositis (p = 0.027) and fatigue (p = 0.015)
were more frequent in the D arm; in most patients
these toxicities were of grade I or/and II. No differences
were observed in post study toxic-deaths or other treat-
ment-related serious adverse-events between the two
arms.
Discussion and conclusions
Single agent docetaxel, or pemetrexed or EFGR TKIs
(erlotinib and gefitinib) represent the standard of care
for second-line treatment for NSCLC patients. However,
the results observed with second-line treatment are gen-
erally poor with response rate of less than 10% and
overall survival of 7-8 months [10-14]. One logical
approach to improve these results is to evaluate combi-
nation regimens. This is the first phase III trial, at least
in our knowledge, comparing docetaxel monotherapy
with a docetaxel/carboplatin doublet in patients with
recurrent or relapsed NSCLC.
The results of the current study demonstrate that
second-line combination treatment with docetaxel/car-
boplatin offers a statistically significant therapeutic
benefit compared to docetaxel monotherapy, in terms
of PFS in patients with NSCLC who were not pre-
viously treated with docetaxel-based chemotherapy.
Indeed, PFS was significantly prolonged in the DC arm
as compared to D arm (p = 0.012). However, although
t h e r ew a sad i f f e r e n c ei nt e r m so fP F St h i sc o u l dn o t
be translated to a significant difference in terms of OS
(p = 0.550). Additionally, no difference was observed
in ORR between the two treatment arms (p = 0.764).
Taken together, these observations suggest that the
higher percentage of patients with stable disease in the
DC arm might have played a role in the differences
observed in PFS.
Table 2 Third-line treatment per study arm
DC (%) D (%) p-value
No treatment 27 (40.3%) 34 (52.3%) 0.222
Chemotherapy 28 (41.8%) 28 (43.1%) 0.999
EGFR-TKIs* 12 (17.9%) 3 (4.6%) 0.026
*Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.
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an acceptable toxicity profile. With the exception of
thrombocytopenia, the DC arm was not associated with
higher toxicity. Indeed, both chemotherapy regimens
were well tolerated, with toxicities being relatively infre-
quent and mild in the vast majority of cases.
The results observed in the single-agent docetaxel arm
of the current study are remarkably similar to those
observed in the phase III trials that led to registration of
docetaxel as second-line treatment in NSCLC [10,11].
Indeed, OS in these trials was 5.7-7.0 months, median
PFS 2.12-2.65 months, and ORR 5.8%-6.7%. The current
study reported a median OS of 7.70 months, a median
PFS of 2.60 months and an ORR of 7.7%. On the other
hand, patients in the docetaxel-carboplatin arm had a
longer OS (10.27 months) when compared to historical
data [15,16]. It is noteworthy that the results of the cur-
rent study are in accordance with the results of a phase
III trial [24] and several randomised phase II trials com-
paring single-agent versus combination regimens as
Table 3 Median TTP and OS by treatment arm
Treatment Group
DC
(n = 67)
D
(n = 65)
Median PFS (mo) 3.33 2.60 P = 0.012
(Log-Rank test)
Min - Max 0.2 - 23.0 0.5 - 17.8
95% CI (2.59 - 4.07) (1.74 - 3.46)
1-year with no progression 11.6% 5.4%
Median survival (months) 10.27 7.70 P = 0.550
(Log-Rank test)
Min - Max 0.7 - 36.8 0.5 - 43.2
95% CI (7.07 - 13.47) (3.39 - 12.01)
1-year survival Kaplan-Meier estimate (%) 43.8% 40.3%
Figure 1 Kaplan-Meier TTP curves by treatment arm.
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these trials demonstrated a statistically significant
improvement in PFS with chemotherapy combinations,
this improvement in PFS was not translated into an OS
prolongation. This observation should be attributed to
the fact that an important proportion of patients with
advanced/metastatic NSCLC have a good performance
status and a acceptable expectancy of life making them
suitable to receive third-line treatment; in the current
study 71 (54%) out of 132 studied patients received
third-line chemotherapy or TKIs.
The results of the current study are also in agreement
with the results of a recently published meta-analysis
based on individual data of 847 patients. Di Maio et al,
compared the efficacy of a doublet chemotherapy regi-
men with single agent treatment as second-line treat-
ment [29]. The conclusion of this meta-analysis was that
although combination treatment was associated with sig-
nificantly higher ORR and significant prolongation of
TTP, this difference was not translated into a significant
survival benefit [29]. Additionally, patients receiving
combination treatment experienced significantly more
toxicity. So, based on the lack of a survival benefit and
the issue of toxicity, someone could argue against the
use of combination regimens in the second-line setting.
Figure 2 Kaplan-Meier survival curves by treatment arm.
Table 4 Haematological & Non-haematological toxicity
per treatment arm
DC
(n = 67)
D
(n = 65)
DC
(n = 67)
D
(n = 65)
P-value
GrIII GrIII GrIV GrIV
N%N%N%N%
Neutropenia 7 10.4 3 4.6 4 6.0 1 1.5 0.098
Anaemia 3 4.5 ------0.791
Thrombocytopenia 2 3.0 ------ < 0.001
Febrile neutropenia - - ------
Nausea --------0.128
Vomiting --------0.999
Diarrhoea 2 3.0 1 1.5 1 1.5 - - 0.999
Stomatitis --------0.027
Constipation --------0.274
Neuromuscular --------0.999
Neurosensory --------0.678
Allergy 2 3 . 0 ----1 1 . 6 0.680
Fatigue - - 6 9.2 - - 1 1.5 0.015
Oedema --------0.680
Other 0.999
P-value for Neutropenia: for grade III/IV vs 0-II between the two groups.
P-value for Anaemia: for grade II-IV vs 0/I between the two groups.
P-value for Thrombocytopenia: for any grade vs grade O between the two
groups.
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lar relevance especially for second-line treatment there
is a need for a regimen with a favourable toxicity profile.
On that basis we selected the bi-weekly mode of doce-
taxel administration because it has been reported that it
is associated with a marked reduction in haematological
toxicity [20].
Another important issue is the timing of administration
of second-line treatment. A recently reported phase III
study [30] demonstrated a statistically significant
improvement in PFS and a non-statistically significant
increase in OS when docetaxel was administered imme-
diately after front-line gemcitabine/carboplatin doublet
compared to its administration at the time of clinical
disease progression; in addition, this strategy was not
associated with increasing toxicity or decreasing QOL.
Practically similar results were obtained with pemetrexed;
indeed, in a recent phase III study, patients without dis-
ease progression after four cycles of platinum-based
front-line treatment who received pemetrexed as mainte-
nance treatment experienced a significantly longer med-
ian PFS and OS compared to patients who received
placebo [31]. Additionally, erlotinib as maintenance treat-
ment after front-line platinum based chemotherapy
resulted in a significant prolongation of PFS [32].
Another controversial issue is the substitution of car-
boplatin for cisplatin and it could be argued our deci-
sion to use carboplatin instead of cisplatin. It is known
that cisplatin-based doublets offer a small survival bene-
fit as front-line treatment, when compared with carbo-
platin-based doublets [33]. On the other hand,
carboplatin has a more favorable toxicity profile when
compared with cisplatin [33]. Additionally, the adminis-
tration of cisplatin requires the need for hydration and
it is relatively contraindicated in patients with cardiopul-
monary co-morbidities and renal insufficiency. Further-
more, given the practical advantage of carboplatin in
terms of ease of administration, it could be argued that
the small benefit achieved with cisplatin relative to car-
boplatin does not justify its use in clinical practice.
Another important issue is whether this study is clini-
cally relevant, since many patients receive platinum-based
first-line treatment. However, it should be noted that no
phase III trial has clearly demonstrated that platinum-
based doublets offer a survival benefit over platinum-free
regimens. Furthermore, a recently published meta-analysis
failed to show any difference in favor of platinum-based
doublets when compared with platinum-free third genera-
tion combinations [17]. Thus, a number of NSCLC
patients could receive platinum-free regimens as first-line
treatment and this trial is relevant for these patients who
could receive platinum derivatives as second line.
In conclusion, the combination of docetaxel/carbopla-
tin was well tolerated as second-line treatment for
NSCLC patients. Although the primary end-point of the
study (prolongation of OS) could not be achieved, the
docetaxel/carboplatin combination was associated with a
significant clinical benefit in terms of PFS. Based on the
results of the current study, docetaxel single-agent
should be considered as one of the “standards” options
for second-line treatment of advanced/metastatic
NSCLC while its combination with carboplatin might be
administered in patients with good PS who were not
previously treated with a platinum-based doublet or
within a well designed clinical trial. Further research is
required for the development of more effective che-
motherapeutic regimens and for the integration of
newer targeted agents into NSCLC treatment.
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